Cellectis (CLLS) Capital Expenditures (2015 - 2026)
Cellectis (CLLS) posted quarterly Capital Expenditures of -$265000.0 for Q1 2026, up 32.91% year-over-year from -$199381.0 in Q1 2025, and down 106.25% quarter-over-quarter from $4.2 million in Q4 2025.
Powered by 
Analysis
Cellectis (CLLS) Capital Expenditures (2015 - 2026) Analysis & Trends
Cellectis' Capital Expenditures history runs 12 years deep, the most recent figure standing at -$265000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 32.91% year-over-year to -$265000.0; the TTM figure through Mar 2026 stood at $2.5 million (up 3.49% YoY), while the FY2025 annual figure was $2.4 million, down 8.63% from the prior year.
- Capital Expenditures for Q1 2026 stood at -$265000.0, down from $4.2 million in the prior quarter.
- The five-year high for Capital Expenditures was $4.6 million in Q4 2024, with the low at -$1.2 million in Q3 2025.
- The 5-year median for Capital Expenditures is -$305000.0 (2025), against an average of $481294.1.
- Peak annual rise in Capital Expenditures reached 146.84% in 2024, while the deepest fall reached 284.44% in 2024.
- Cellectis' Capital Expenditures stood at $4.4 million in 2022, then tumbled by 57.69% to $1.9 million in 2023, then surged by 146.84% to $4.6 million in 2024, then retreated by 8.12% to $4.2 million in 2025, then slumped by 106.25% to -$265000.0 in 2026.
- Business Quant data shows CLLS's Capital Expenditures at -$265000.0 in Q1 2026, $4.2 million in Q4 2025, and -$1.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -253,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -253,000.00 |
| Mar 31, 2026 | -265,000.00 |
| Dec 31, 2025 | -479,000.00 |
| Sep 30, 2025 | -1.18 Mn |
| Jun 30, 2025 | -305,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Dec 31, 2024 | -550,000.00 |
| Sep 30, 2024 | -3.29 Mn |
| Jun 30, 2024 | 1.47 Mn |
| Mar 31, 2024 | -218,000.00 |
| Dec 31, 2023 | -276,000.00 |
| Sep 30, 2023 | -1.28 Mn |
| Jun 30, 2023 | 696,000.00 |
| Mar 31, 2023 | -213,000.00 |
| Dec 31, 2022 | -442,000.00 |
| Sep 30, 2022 | -3.53 Mn |
| Jun 30, 2022 | 2.17 Mn |
| Mar 31, 2022 | -626,000.00 |
| Dec 31, 2021 | -289,000.00 |
| Sep 30, 2021 | -31.90 Mn |